Abstract
Hemangiosarcoma (HSA) is a malignant neoplasm originating from endothelial cells. In dogs it is a very aggressive neoplasia, where metastases are frequent and existing therapies provide only a minimal benefit. The investigation of new therapeutic alternatives is necessary for the development of more effective treatments against this neoplasia. A recruited and purified Urokinase (uPA) and …